LIM-domain-only 4 (LMO4) enhances CD8 ⁺ T-cell stemness and tumor rejection by boosting IL-21-STAT3 signaling.

Autor: Schelker RC; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany. roland.schelker@ukr.de.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. roland.schelker@ukr.de.; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. roland.schelker@ukr.de.; Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany. roland.schelker@ukr.de., Fioravanti J; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Mastrogiovanni F; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Baldwin JG; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Rana N; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; Next Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany., Li P; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Chen P; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Vadász T; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Spolski R; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Heuser-Loy C; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Slavkovic-Lukic D; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Noronha P; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Damiano G; Immuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy., Raccosta L; Immuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy., Maggioni D; Immuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy., Pullugula S; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Lin JX; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Oh J; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Grandinetti P; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Lecce M; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Hesse L; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; University of Regensburg, Regensburg, Germany., Kocks E; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; University of Regensburg, Regensburg, Germany., Martín-Santos A; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Gebhard C; Next Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany., Telford WG; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Ji Y; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Restifo NP; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Russo V; Immuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy., Rehli M; Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.; Next Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany., Herr W; Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.; National Center for Tumor Diseases, WERA Site, Würzburg-Erlangen-Regensburg-Augsburg, Germany.; Center for Immunomedicine in Transplantation and Oncology, University Hospital Regensburg, Regensburg, Germany., Leonard WJ; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. leonardw@nhlbi.nih.gov., Gattinoni L; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany. luca.gattinoni@lit.eu.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. luca.gattinoni@lit.eu.; University of Regensburg, Regensburg, Germany. luca.gattinoni@lit.eu.; Center for Immunomedicine in Transplantation and Oncology, University Hospital Regensburg, Regensburg, Germany. luca.gattinoni@lit.eu.

Publikováno v: Signal transduction and targeted therapy [Signal Transduct Target Ther] 2024 Aug 09; Vol. 9 (1), pp. 199. Date of Electronic Publication: 2024 Aug 09.

Lower blood pH as a strong prognostic factor for fatal outcomes in critically ill COVID-19 patients at an intensive care unit: A multivariable analysis.

Autor: Kieninger M; Department of Anesthesiology, University Medical Center Regensburg, Regensburg, Germany., Sinning A; Department of Anesthesiology, University Medical Center Regensburg, Regensburg, Germany., Vadász T; Department of Infection Prevention and Infectious Diseases, University Medical Center Regensburg, Regensburg, Germany., Gruber M; Department of Anesthesiology, University Medical Center Regensburg, Regensburg, Germany., Gronwald W; Institute of Functional Genomics, University of Regensburg, Regensburg, Germany., Zeman F; Center for Clinical Studies, University Medical Center Regensburg, Regensburg, Germany., Lunz D; Department of Infection Prevention and Infectious Diseases, University Medical Center Regensburg, Regensburg, Germany., Dienemann T; Department of Surgery, University Medical Center Regensburg, Regensburg, Germany., Schmid S; Department of Internal Medicine I, University Medical Center Regensburg, Regensburg, Germany., Graf B; Department of Infection Prevention and Infectious Diseases, University Medical Center Regensburg, Regensburg, Germany., Lubnow M; Department of Internal Medicine II, University Medical Center Regensburg, Regensburg, Germany., Müller T; Department of Internal Medicine II, University Medical Center Regensburg, Regensburg, Germany., Holzmann T; Department of Infection Prevention and Infectious Diseases, University Medical Center Regensburg, Regensburg, Germany., Salzberger B; Department of Infection Prevention and Infectious Diseases, University Medical Center Regensburg, Regensburg, Germany., Kieninger B; Department of Infection Prevention and Infectious Diseases, University Medical Center Regensburg, Regensburg, Germany.

Publikováno v: PloS one [PLoS One] 2021 Sep 29; Vol. 16 (9), pp. e0258018. Date of Electronic Publication: 2021 Sep 29 (Print Publication: 2021).

Severe COVID-19 infection: An institutional review and literature overview.

Autor: Akpoviroro, Ogheneyoma¹ (AUTHOR) o.akpoviroro@gmail.com, Sauers, Nathan Kyle² (AUTHOR), Uwandu, Queeneth¹ (AUTHOR), Castagne, Myriam³ (AUTHOR), Akpoviroro, Oghenetejiro Princess⁴ (AUTHOR), Humayun, Sara¹ (AUTHOR), Mirza, Wasique¹ (AUTHOR), Woodard, Jameson¹ (AUTHOR)

Publikováno v: PLoS ONE. 8/20/2024, Vol. 19 Issue 8, p1-34. 34p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Experience with Once-Daily and Twice-Daily Slow-Release Frusemide in Hypertension

Autor: Vadász, T A, Chadha, Dev R

Publikováno v: Journal of International Medical Research; July 1982, Vol. 10 Issue: 4 p199-203, 5p